LGT Fund Management Co Ltd. Acquires 990 Shares of IDEXX Laboratories, Inc. $IDXX

LGT Fund Management Co Ltd. raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 112.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,870 shares of the company’s stock after buying an additional 990 shares during the quarter. LGT Fund Management Co Ltd.’s holdings in IDEXX Laboratories were worth $1,051,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in IDXX. Arlington Capital Management Inc. grew its stake in shares of IDEXX Laboratories by 4.8% in the first quarter. Arlington Capital Management Inc. now owns 479 shares of the company’s stock worth $269,000 after acquiring an additional 22 shares during the last quarter. Diversify Wealth Management LLC raised its stake in IDEXX Laboratories by 87.6% during the 1st quarter. Diversify Wealth Management LLC now owns 2,097 shares of the company’s stock valued at $1,161,000 after purchasing an additional 979 shares during the last quarter. Valmark Advisers Inc. boosted its holdings in IDEXX Laboratories by 13.5% in the 1st quarter. Valmark Advisers Inc. now owns 2,188 shares of the company’s stock valued at $1,229,000 after purchasing an additional 260 shares during the period. Carnegie Investment Counsel boosted its holdings in IDEXX Laboratories by 1.3% in the 1st quarter. Carnegie Investment Counsel now owns 2,000 shares of the company’s stock valued at $1,124,000 after purchasing an additional 25 shares during the period. Finally, UNIVEST FINANCIAL Corp grew its position in IDEXX Laboratories by 1.9% in the 1st quarter. UNIVEST FINANCIAL Corp now owns 6,590 shares of the company’s stock worth $3,703,000 after purchasing an additional 126 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $563.57 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The firm’s 50-day simple moving average is $555.09 and its 200-day simple moving average is $603.76. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The firm has a market cap of $44.46 billion, a P/E ratio of 41.50, a price-to-earnings-growth ratio of 3.08 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IDXX. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. UBS Group decreased their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 25th. Finally, Citigroup assumed coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.